Myriad Pharmaceuticals, Inc.

Myriad Pharmaceuticals, Inc.

Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection. Its pipeline includes clinical and pre-clinical product candidates with mechanisms of action and novel chemical structures. The company's product candidates in clinical development include Azixa (MPC-6827), which is under Phase II clinical trial for the treatment of glioblastoma multiforme and metastatic melanoma; MPC-4326 for HIV-1 infection under Phase IIb clinical trial; and MPC-3100, a Phase I clinical trial product candidate for cancer treatment. Its products in preclinical programs comprise MPI-443803, an orally available, brain penetrant, microtubule destabilizing agent for the treatment of cancer; and MPI-461359, an orally available maturation inhibitor for the treatment of HIV-1 infection, as well as MPI-479605 for the treatment of cancer. The company also offers ProNet, a proprietary database of protein-protein interactions, which encompasses interactions between approximately 10 million protein fragments constructed from various organ tissues, including heart, brain, kidney, liver, breast, and prostate. Myriad Pharmaceuticals, Inc. is based in Salt Lake City, Utah.

Contact Details

Office Address

Myriad Pharmaceuticals, Inc.
320 Wakara Way
Salt Lake City, UT, USA 84108
Phone: (801) 584-3600
Fax: (801) 584-3640

Executives

Chief Exec. Officer

Dr. Adrian N. Hobden

Chief Financial Officer

Mr. Robert J. Lollini

Business Reviews for Myriad Pharmaceuticals, Inc.

Related Companies